The transcription factor E2F1 has a key function during S phase progression and apoptosis. It has been well-demonstrated that the apoptotic function of E2F1 involves its ability to transactivate pro-apoptotic target genes. Alternative splicing of pre-mRNAs also has an important function in the regulation of apoptosis. In this study, we identify the splicing factor SC35, a member of the SerRich Arg (SR) proteins family, as a new transcriptional target of E2F1. We demonstrate that E2F1 requires SC35 to switch the alternative splicing profile of various apoptotic genes such as c-flip, caspases-8 and -9 and Bcl-x, towards the expression of pro-apoptotic splice variants. Finally, we provide evidence that E2F1 upregulates SC35 in response to DNA-damaging agents and show that SC35 is required for apoptosis in response to these drugs. Taken together, these results demonstrate that E2F1 controls pre-mRNA processing events to induce apoptosis and identify the SC35 SR protein as a key direct E2F1-target in this setting. Cell Death and Differentiation (2008) 15, 1815-1823 doi:10.1038/cdd.2008 published online 19 September 2008 Pre-mRNA splicing is an essential step for the expression of most genes in higher eukaryotic cells. This process has emerged as an important mechanism of genetic diversity as about 74% of human genes undergo alternative splicing, leading to the production of various protein isoforms.
Pre-mRNA splicing is an essential step for the expression of most genes in higher eukaryotic cells. This process has emerged as an important mechanism of genetic diversity as about 74% of human genes undergo alternative splicing, leading to the production of various protein isoforms.
1 SC35 belongs to the serine/arginine-rich (SR) protein family, one of the most important class of splicing regulators. Members of the SR family have a modular structure consisting of one or two copies of an N-terminal RRM (RNA-recognition motif) followed by a C terminus rich in serine and arginine residues known as the RS domain. They act at multiple steps of spliceosome assembly and participate in both constitutive and alternative splicing. 2 Together with most of the other splicing factors, SR proteins localize to nuclear subregions termed nuclear speckles. 3 Extensive serine phosphorylation of the RS domain has an important function in the regulation of both the localization and the activities of SR proteins. 4 Although the splicing functions of SR proteins have been well documented in vitro, their roles and physiological targets in vivo are less well known. However, based on gene targeting experiments demonstrating that they are required for cell viability and/or animal development, SR proteins undoubtedly control essential biological functions.
Apoptosis is one of the cellular processes in which alternative splicing has an important regulatory function. Indeed, a remarkable number of transcripts that encode proteins involved in the apoptotic pathway are subjected to alternative splicing. This usually drives the expression of proteins with opposite functions, either pro-or anti-apoptotic. 5 Interestingly, changes in SR protein phosphorylation have been observed upon apoptotic stimulation following activation of the Fas receptor. 6 In addition, in vitro overexpression experiments have suggested a potential role for SR proteins in the control of the splicing of pre-mRNAs encoding apoptotic regulators [7] [8] Moreover, depletion of the ASF/SF2 SR protein has been reported to induce apoptosis. [8] [9] Nevertheless, whether individual SR proteins are necessary to modulate alternative splicing of mRNAs encoding apoptotic factors remains largely unknown, as well as the factors that control expression and/or activity of SR proteins in this context.
The E2F1 transcription factor belongs to the E2F family encompassing eight members involved in a diverse array of essential cellular functions. 10 E2F1 is best-known for its role in driving cell cycle progression in S phase. In addition, E2F1 can induce apoptosis by mechanisms involving with or without transcriptional function. We previously demonstrated the ability of E2F1 to trigger apoptosis through caspase-8 activation at the death-inducing signaling complex and showed that E2F1 acts through specific downregulation of the cellular FLICE-inhibitory protein short isoform, c-FLIP short . 11 As c-flip predominantly encodes two isoforms arising from alternative splicing, namely c-FLIP short and c-FLIP long , we postulated that E2F1 could control the expression and/or activity of some splicing factors. In this study, we identify the SC35 splicing factor as a direct transcriptional target of E2F1 and show that SC35 is involved in the ability of E2F1 to trigger apoptosis through downregulation of c-FLIP short . Importantly, we demonstrate that E2F1 and SC35 also cooperate to switch the alternative splicing pattern of caspases-8 and -9 as well as of Bcl-x, towards the expression of pro-apoptotic isoforms. Finally, we provide evidence that E2F1 promotes the accumulation of SC35 in cells treated with DNA-damaging agents, and show that SC35 is required for induction of apoptosis in this setting. Taken together, these results demonstrate that E2F1 and SC35 proteins control premRNA processing events to promote apoptosis.
Results
E2F1 upregulates SC35 protein expression. We previously established a model of stable E2F1-inducible clones in the H358 cell line derived from a human lung adenocarcinoma. 11 Here, we exploit this model to test whether E2F1 can control the expression pattern of three members of the SR protein family, one of the most important class of splicing regulators, namely SC35, SRp20 and SF2/ASF. Immunoblotting experiments demonstrated a 3 to 4-fold increased expression of SC35 in cells overexpressing E2F1, whereas the total level of SRp20 and SF2/ASF was not affected (Figure 1a , left panel). This effect required the DNAbinding activity of E2F1 as overexpression of an E2F1(E132) DNA-binding defective mutant did not affect SC35 protein level ( Figure 1a , right panel).
To confirm these data, we knocked down E2F1 expression by using small interfering RNAs (siRNAs) in the H69 and H810 neuroendocrine lung carcinoma cell lines that physiologically express high levels of E2F1, and analyzed SC35, SRp20 and SF2/ASF expression by western blotting. As shown in Figure 1b , the silencing of E2F1 was accompanied by marked downregulation of the endogenous SC35 protein in both cell lines as compared with cells transfected with mismatch siRNA. In contrast, the expression of SRp20 and SF2/ASF proteins was not affected. In addition, we observed that SC35 protein levels were strongly reduced in E2F1 knockout murine embryonic fibroblast (MEF) as compared with wild-type MEF, whereas those of SRp20 and SF2/ASF did not change (Figure 1c) . Taken together, these data demonstrate that SC35 expression is positively regulated by E2F1.
SC35 is a direct transcriptional target of E2F1. To test whether E2F1 controls SC35 expression at the transcriptional level, we performed reverse transcription (RT)-PCR experiments using primers localized at the 5 0 -end of the sc35 ORF. The data showed that expression of sc35 mRNA was induced by E2F1 but not by the mutant E2F1(E132) (Figure 2a) . To go further, we performed Chloramphenicol Acetyl Transferase (CAT) experiments using a pR264-CAT plasmid that contains the 1 kb human sc35 promoter upstream of CAT cDNA. 12 Co-transfection of H1299 (Figure 2b ) or SAOS2 (data not shown) cells with pR264-CAT vector and increasing amounts of an E2F1 expression vector resulted in a dose-dependent increase of CAT activity. These results indicated that E2F1 can transactivate the promoter of sc35. To confirm these data in vivo, we performed chromatin immunoprecipitation (ChIP) experiments in the H358/Tet-On/ E2F1 cells cultured in the presence of doxycyclin (Figure 2c , upper panel). As a positive control of ChIP assays, we used the proximal human Skp2 promoter that was recently reported as a target of E2F1. 13 In our conditions, binding of E2F1 to the proximal Skp2 gene promoter was clearly detected whereas no binding was observed with the Gapdh promoter ( Figure 2c, upper panel) . Importantly, the sc35 promoter fragment (À296/À79) that encompasses two putative E2F1-binding sites was precipitated by an anti-E2F1 antibody (Figure 2c , upper panel). To confirm that SC35 was a direct target of E2F1, endogenous E2F1 was immunoprecipitated from H1299 cells and ChIP experiments were performed. As shown (Figure 2c , lower panel), endogenous E2F1 clearly bound to the sc35 promoter in these cells. Taken together, these results identify sc35 as a direct transcriptional target of E2F1.
Wild-Type E2F1 -/-
E2F1 promotes SC35-dependent apoptosis through modulation of FLIP long /FLIP short ratio. As we previously demonstrated the ability of E2F1 to induce apoptosis through downregulation of the c-FLIP short protein isoform, 11 we next analyzed whether SC35 has a function in this setting. By the use of sc35 siRNAs and Hoechst staining, we first observed that neutralization of SC35 strongly reduced the number of apoptotic cells in response to E2F1 (Figure 3a) . Therefore, these results indicated that SC35 is required for E2F1-induced apoptosis. Importantly, RT-PCR (Figure 3b , left panel) and immunoblot analyses (Figure 3b , right panel) revealed that downregulation of both flip short mRNA and protein levels were also prevented in these conditions. A high level of both c-FLIP protein isoforms has been found in many tumor cells and was correlated with resistance to FAS-and TRAIL-induced apoptosis, two death receptor ligands.
14 Consistently, we previously reported that the downregulation of c-FLIP Short by E2F1 was sufficient to restore the sensitivity of tumor cells to these ligands. 11 In this study, we showed that neutralization of sc35 expression overrode the ability of E2F1 to sensitize H358 cells to FasL (Figure 3c ) as well as to TRAIL (data not shown) treatments. Collectively, our data demonstrate that E2F1 induces apoptosis through SC35-dependent modulation of the FLIP Long / FLIP Short ratio, at the expense of the FLIP Short protein isoform.
E2F1 and SC35 co-regulate the splicing pattern of caspase-8, caspase-9 and Bcl-x pre-mRNAs in favor of pro-apoptotic splice variants. As the expression of numerous apoptotic genes is regulated by pre-mRNA alternative splicing, 5 we undertook a series of experiments to test whether E2F1 and SC35 can also affect the ratio of other apoptotic splice variants. Various caspases are subjected to alternative splicing. Alternative splicing of casp-2 proceeds through selective insertion or removal of exon 9 giving rise to anti-apoptotic caspase-2S and proapoptotic caspase-2L isoforms respectively. 7 The use of a distant splice donor site at the 3 0 -end of exon 8 of human caspase-8 pre-mRNA leads to the synthesis of an alternative splice variant, caspase-8L, a competitive inhibitor of caspase-8. [15] [16] The inclusion or exclusion of an exon cassette in caspase-9 causes the expression of two splice variants, namely the pro-apoptotic caspase-9a and antiapoptotic caspase-9b. [17] [18] To assess whether E2F1 induces changes in the alternative splicing profile of these caspases pre-mRNAs, RNAs recovered from non-induced or induced H358/Tet-On/E2F1 cells were analyzed by RT-PCR using primers specific for each caspase splice variant (Figure 4a) . The results showed that E2F1 increased the expression of pro-apoptotic caspases-2L, -8a and -9a mRNA levels and decreased those of anti-apoptotic caspases-8L and -9b (Figure 4b ). In contrast, these effects were not observed with mutant E2F1(E132). Interestingly, we were unable to detect the caspase-2S transcript in our cells. Altogether, these data indicate that E2F1 can switch the splicing pattern of caspases-8 and -9 in favor of pro-apoptotic isoforms. Therefore, besides its ability to transactivate caspases-8 and -9 genes, 19 E2F1 also controls their alternative splicing. Bcl-x is a member of the bcl-2 gene family that also has a key function in apoptosis. Several splice isoforms of Bcl-x have been reported. The use of a 5 0 proximal site generates the Bcl-x L long isoform, which protects cells against apoptosis. In contrast, the use of a 5 0 distal site results in the synthesis of a short pro-apoptotic Bcl-x S isoform. 20 To analyze whether E2F1 regulates the splicing pattern of Bcl-x, we performed RT-PCR analysis with specific primers in H358/Tet-On/E2F1 cells (Figure 4a) . The results showed that expression of E2F1 induced a concomittant decrease of Bcl-x L and increase of Bcl-x S mRNA levels ( Figure 4c , upper panel). As was observed for caspase regulation, the mutant E2F1(E132) had no effect on bcl-x splicing. Western blotting with Bcl-x antibodies specific for each isoform confirmed the RT-PCR results (Figure 4c, lower panel) . Therefore, these data demonstrate that E2F1 also controls the alternative splicing of Bcl-x.
Finally, we investigated whether SC35 was involved in these effects. siRNAs targeting sc35 were transfected in H358/Tet-On/E2F1 cells, and expression of caspases and Bcl-x splice variants was analyzed by RT-PCR. In the absence of E2F1 induction, the knockdown of sc35 using two independent siRNAs (Figure 4d and Supplementary  Figure 1 ) did not significantly alter the level of caspases-8L, -8a, -9a or -9b mRNAs, nor that of Bcl-x L or Bcl-x S . Importantly, the induction of E2F1 expression in these cells deprived of SC35 did not affect the splicing pattern of these genes (Figure 4d and Supplementary Figure 1) . Furthermore, when we performed RT-PCR analyses in A549 cells transiently transfected with a vector encoding SC35, we found that overexpression of SC35 affected the splicing profile of caspase-8, -9 and Bcl-x pre-mRNAs in a similar way than did E2F1 (compare Figure 4e to b and c) and induced apoptosis (data not shown). Altogether, these results demonstrate that E2F1 requires SC35 to regulate the pre-mRNA alternative splicing of apoptotic genes.
E2F1 and SC35 proteins are upregulated and required for apoptosis in response to genotoxic stresses. So far, our results demonstrate the ability of overexpressed E2F1 and SC35 to modify the splicing pattern of various apoptotic genes. Thus, we next attempted to identify in which physiological context both proteins could cooperate to induce apoptosis. It is now well-known that DNA-damaging agents stabilize E2F1 and induce its transcriptional activity towards apoptotic genes thereby causing apoptosis. [21] [22] In agreement with previous reports, treatment of H358 cells with either methylmethanesulfonate or cyclophosphamide, two alkylating agents that create inter-strand DNA crosslinks, significantly increased E2F1 expression as detected by immunoblotting (Figure 5a, upper panel) . In these conditions, upregulation of E2F1 was accompanied by an increase of SC35 protein and mRNA expression (Figure 5a , upper panels), as well as by the induction of apoptosis (Figure 5a, lower panel) . In cyclophosphamide-treated cells, the neutralization of E2F1 using siRNAs prevented the accumulation of SC35 (Figure 5b ), indicating that E2F1 was involved in SC35 induction. In addition, as detected by ChIP experiments, the binding of endogenous E2F1 to the sc35 promoter was increased following drug treatment, indicating that SC35 is a direct target of E2F1 in response to DNA-damaging agents (Figure 5c ). Furthermore, inhibiting SC35 expression strongly repressed apoptosis following cyclophosphamide treatment, as detected by immunoblotting of pro-or cleaved caspase-3 and Hoechst 33342 staining (Figure 5d ). Taken together, these results demonstrate that E2F1 requires SC35 to induce apoptosis in response to genotoxic stresses.
Finally, we analyzed whether E2F1 and SC35 acted through regulation of the alternative splicing of apoptotic genes and studied the expression pattern of caspases -2, -8 and -9 as well as Bcl-x splice variants by RT-PCR following cyclophosphamide treatment. As shown in Figure 6a (left panel), an increase of pro-apoptotic caspase-9a and Bcl-x S mRNA levels was observed in cyclophosphamide-treated
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Discussion
E2F1 is a transcription factor that has a critical function in cell cycle progression by favoring entry into S phase. Besides its RT-PCR analysis for detection of caspases -2, -8, -9 and Bcl-x splice variants were performed as described earlier in Figure 4b and c. Right panel: western blot analysis was performed using specific anti-SC35, anti-Bcl-x L and anti-Bcl-x S antibodies. Actin was used as a loading control. (b) H358 cells were transfected for 48 h with either mismatch or e2f1 or sc35 siRNA and treated ( þ ) or not (À) for 24 additional hours with cyclophosphamide (50 mM). RT-PCR (upper panel) and western blot (lower panel) analyses of Bcl-x or caspase-9 splice variants were performed as previously described. g3pdh and actin were used as internal controls for RT-PCR and immunoblotting experiments, respectively function in cell cycle control, E2F1 is also widely accepted as an inducer of apoptosis. It has been well-demonstrated that E2F1 promotes apoptosis through both transcriptiondependent and -independent mechanisms. So far, numerous apoptotic genes whose transcription is enhanced by E2F1 have been identified. 10 In this study, we show that E2F1 switches the alternative splicing pattern of key apoptotic genes in favor of their pro-apoptotic splice variants, and identify the SC35 protein, a member of the SR family of splicing regulators, as a key direct target of E2F1. Interestingly, two high throughput studies using ChIP on Chip analysis 23 or DNA microarrays 24 previously suggested that SC35 is an E2F1-regulated gene. In this study, we provide the first evidence of a direct functional link between E2F1 and SC35 proteins to regulate cellular apoptosis. Therefore, besides its ability to transactivate pro-apoptotic target genes, E2F1 is also able to control pre-mRNA processing events to induce apoptosis.
It has now emerged from the literature that splicing not only depends on the interaction of splicing factors with their target pre-mRNAs, but is also coupled to transcription. 25 Indeed, variations of pol II promoter structure can lead to differences in alternative splicing of the transcript [26] [27] and components of the spliceosome such as the p54nrb (p54 nuclear RNAbinding protein) and PSF (polypyrimidine tract-binding protein-associated splicing factor) RNA-binding proteins are involved in both transcription and splicing processes. 28 (for review). In addition, transcriptional coregulators of the nuclear receptor family recruited at the promoter level not only enhances the transcriptional activity of this promoter, but also affects the nature of the splice variants produced. [28] [29] [30] Moreover, some transcription factors have been reported to bind to proteins of the spliceosome and/or display dual functions in splicing and transcription. [31] [32] Taken together, these results indicate a function for proteins controlling transcription in splicing regulation. In this study, we demonstrate that the transcription factor E2F1 transactivates the expression of sc35, a component of the spliceosome and that both proteins regulate pre-mRNA processing events. Altogether, these results strengthen the connection between the transcriptional and splicing machineries. We show that E2F1 alters the splicing pattern of some of its transcriptional targets such as c-flip (Figure 3b) , caspases-8 and -9 (Figures 4b  and d) . As an increased level of caspases-8 and -9 transcripts was also detected in this context, it is possible that the transactivating functions of E2F1 cooperate with SC35 accumulation to regulate pre-mRNA processing events. Interestingly, the expression of c-flip mRNA was apparently not affected by E2F1 in the same conditions (Figure 3a) . It was recently shown that the Spi-1/PU.1 transcription factor could modify alternative splicing of a transcriptional target gene, without modulation of its mRNA transcription. 32 Therefore, another but not exclusive possibility is that E2F1 acts as a scaffold protein to drive SC35 to the nascent transcribed RNA of some of its target genes, according to the cell-specific promoter occupation model. 25 Apoptosis is one of the cellular processes in which alternative splicing has important regulatory functions. 5 Several components of the splicing machinery have already been implicated in apoptotic processes. For example, depletion of SF2/ASF 8 induces apoptosis. In addition, overexpression of SC35 alters the splicing of caspase-2 mRNA, in favor of the pro-apoptotic isoform accumulation. 7 Furthermore, phosphorylation of SR proteins, which is known to control their sub-cellular localization as well as their activities, has been reported during apoptosis. However, the upstream signaling molecules that regulate the expression and/or activity of SR proteins during apoptosis, as well as the endogenous targets of SR proteins in this context remain largely unknown. In this study, we provide evidence that E2F1 triggers apoptosis through SC35 accumulation and we demonstrate that both proteins cooperate to affect the splicing pattern of caspase-8, caspase-9, flip and bcl-x genes, in favor of proapoptotic splice variants. Taken together, our data identify SC35 as a new mediator of E2F1-induced apoptosis and identify some of its endogenous targets in this setting.
Alteration of alternative splicing is believed to contribute to the resistance of tumor cells to chemotherapy, notably through overexpression of anti-apoptotic splice variants. 34, 35 However, the molecular mechanisms involved in such processes remain largely unknown. Importantly, and consistent with a function of SR proteins during the response to DNA damage, it has been previously shown that SC35 accumulates following g-irradiation. 36 In addition, it was recently reported that the expression of SRp55, another member of the SR protein family, is upregulated and required for apoptosis of p53-deficient cells after mitomycin C treatment. 37 In this study, we demonstrate that SC35 is upregulated by an E2F1-dependent pathway in response to methylmethanesulfonate or cyclophosphamide treatment. Furthermore, we show that the E2F1 and SC35 proteins are required for apoptosis of DNA-damaged cells and control Bcl-x and caspase-9 premRNAs alternative splicing at the expense of anti-apoptotic splice variants. Therefore, our data strongly suggest that E2F1 and SC35 are key determinants of the cellular response to chemotherapeutic agents.
To conclude, we highlight the first functional connection between the transcription factor E2F1 and a component of the splicing machinery, SC35, in the control of cellular apoptosis. It is well-known that abnormalities in E2F-signalling pathways contribute to tumorigenesis.
38 Accordingly, we previously described a differential pattern of E2F1 protein expression in human lung tumors. 39 Interestingly, some SR proteins are overexpressed in ovarian cancer 40 and SF2/ASF was recently assessed as a proto-oncogene in human tumors. 41 Therefore, it remains to be determined whether alterations of both E2F1 and SC35 proteins could cooperate to promote carcinogenesis.
Materials and Methods
Cell lines, treatment, apoptotic assay, plasmids and transfection. A549, H358, H1299 and H69 human lung carcinoma cell lines were cultured as described earlier. 42 The H810 large cell neuroendocrine lung carcinoma cell line was cultured in 5% CO 2 at 371C in RPMI-1640 medium supplemented with 5% (v/v) FCS, 0.005 mg/ml insulin, 0.01 mg/ml transferrin, 30 nM sodium selenite, 10 nM hydrocortisone, 10 nM b-estradiol and 10 mM HEPES. MEFs wild-type and E2F1À/À were cultured in DMEM (GIBCO) supplemented with 10% (v/v) heatinactivated FCS. The human lung adenocarcinoma H358/Tet-On/E2F1 and Tet-On/ E2F1 (E132) inducible clones were obtained as previously described. 11 Apoptosis was evaluated by scoring the percentage of apoptotic cells on 500 cells after Hoechst 33342 staining. Transient transfections were carried out using Fugene 6 (Roche Diagnostic). Plasmids used in transient transfections were pcDNA3, pCMV-E2F-1, pcDNA3-HA-SC35 and pR264-CAT. Recombinant soluble human FLAGtagged FasL was purchased from Alexis (San Diego, CA, USA). Methanesulfonic acid methyl ester and cyclophosphamide monohydrate were all purchased from Sigma (Saint Quentin Fallavier, France).
Antibodies. The anti-E2F1 (C-20), anti-SC35 (H-55) and anti-Bcl-x L (H5) antibodies were purchased from Santa Cruz, the anti-Bcl-x S (Ab-1) from Oncogene Research, the anti-E2F1 (KH95) and anti-procaspase-3 from Pharmingen, the anti-FLIP (NF6) from Alexis, the anti-actin (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) from Sigma, the anti-SC35 (4F-11) from Euromedex and the anti-SRp20 (7B4) and anti-SF2/ASF from Zymed. Cleaved caspase-3 (Asp175) was from Cell Signaling.
CAT assays. For CAT assay measurements, 2 Â 10 5 cells per well were seeded in duplicate in 6-well plates, and transfected with the pR264CAT plasmid in the presence or absence of increasing amounts of pCMV-E2F1 vector. pR364CAT vector contains the 1 kb human sc35 promoter 12 and encompasses two putative E2F1-binding sites at -170 (TTTGGCCCG) and -236 (TTTCGCGGG) bp upstream of the transcription start site. Transfection was performed using Fugene 6 according to the manufacturer's instructions, and CAT activity was measured 24-48 h after transfection using CAT ELISA (Roche Diagnostic). CAT activity was then normalized in each sample according to the protein amount.
Chromatin immunoprecipitation experiments. Chromatin immunoprecipitation experiments were performed in H358 cells, H1299 cells or H358/ Tet-On/E2F1 cells cultured in the presence of 1 mg/ml doxycyclin for 24 h. An equal amount of chromatin (25 mg) was precleared and immunoprecipitated with a polyclonal antibody specific for E2F1 (C-20, Santa Cruz) or unrelated rabbit IgG or no antibody, overnight at þ 41C. Co-immunoprecipitated chromatin was analyzed for the presence of sc35 promoter DNA between -296 and -79 bp, upstream of the sc35 transcription start site, by semiquantitative PCR. This fragment encompasses two putative E2F1-binding sites at À170 and -236 bp upstream of the transcription start site. The primers used were as follow: forward 5 0 -GAGCACCTCCTCTT CCTCCTG-3 0 and reverse 5 0 -CCGGAAATGAAACCTTCTGA-3 0 . PCR conditions were 941C for 3 min, (941C 30 s, 551C 30 s, 721C 30 s) for 36 cycles, and 721C for 10 min. For Skp2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter analysis, the specific primers used were SKP2-95 5 0 -CTCCCCGC CTACCCCGTGG-3 0 , SKP2-þ 135 5 0 -CAGACCCGCTAAGCCTAGCAACG-3 0 , GAPDH forward 5 0 -AGCTCAGGCCTCAAGACCTT-3 0 and GAPDH reverse 5 0 -AA GAAGATGCGGCTGACTGT-3 0 as previously described. 13 PCR conditions were 941C for 3 min, (941C 30 s, 571C for GAPDH or 631C for Skp2 30 s, 721C 30 s) for 36 cycles, and 721C for 10 min. Signals obtained on ethidium bromide-stained gels were quantified using ImageJ software and each ChIP DNA sample was normalized according to the corresponding input DNA sample.
Transfection of siRNA oligonucleotides. The sequences designed to specifically target human sc35 and e2f1 RNAs were as follows: sc35 (1) RT-PCR analyses of alternative splice transcripts. Total cellular RNAs were isolated using Trizol reagent (Invitrogen). In all conditions, 1 mg of total RNA was reverse transcribed using oligo(dT) primer and MMLV reverse transcriptase (Invitrogen) according to the manufacturer's protocol. The different primer sequences used in this study as well as the PCR conditions are recapitulated in Table 1 . Amplification of a cDNA fragment of G3PDH (Invitrogen) was performed in the same PCR as an internal control. PCR products were run on a 1-2% agarose gel and visualized by ethidium bromide staining.
Immunoblotting and immunoprecipitation experiments. Immunoblotting experiments were performed as described earlier. 
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